Prot #19-188: NU DF21B07: Evaluation of Talazoparib, a PARP Inhibitor, in Patients with Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Project: Research project

Project Details

StatusActive
Effective start/end date7/22/22 → 7/22/25

Funding

  • Dana-Farber/Partners CancerCare, Inc. ((OE) Prot #19-188 // (OE) Prot #19-188)
  • Pfizer Inc. ((OE) Prot #19-188 // (OE) Prot #19-188)